Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia

CONCLUSIONS: Our results suggest that dasatinib-based low-intensity chemotherapy is safe and effective as an induction strategy in the Chinese population. Allo-HSCT plays a crucial role in the long-term outcomes of patients with Ph+ ALL.CLINICAL TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov as NCT02690922.PMID:38616308 | DOI:10.1080/17474086.2024.2343885

Source: Expert Review of Hematology - April 14, 2024 Category: Hematology Authors: Yizhou Peng Jinjin Huang Jin Yin Fankai Meng Yang Cao Liang Huang Dengju Li Yicheng Zhang Donghua Zhang Li Meng Zhiqiang Han Zhenya Hong Source Type: research